167 related articles for article (PubMed ID: 23052636)
21. [Combined assay of soluble CD30 and hepatocyte growth factor for diagnosis of acute renal allograft rejection].
Li CJ; Yu LX; Xu J; Fu SJ; Deng WF; Du CF; Wang YB
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):241-2. PubMed ID: 18250052
[TBL] [Abstract][Full Text] [Related]
22. Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes.
Yang JL; Hao HJ; Zhang B; Liu YX; Chen S; Na YQ
Transplant Proc; 2008 Dec; 40(10):3381-3. PubMed ID: 19100394
[TBL] [Abstract][Full Text] [Related]
23. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
Rodríguez LM; París SC; Arbeláez M; Cotes JM; Süsal C; Torres Y; García LF
Hum Immunol; 2007 Aug; 68(8):652-60. PubMed ID: 17678719
[TBL] [Abstract][Full Text] [Related]
24. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
[TBL] [Abstract][Full Text] [Related]
25. Association between serum soluble CD30 and serum creatinine before and after renal transplantation.
López-Hoyos M; San Segundo D; Benito MJ; Fernández-Fresnedo G; Ruiz JC; Rodrigo E; Gómez-Alamillo C; Benito A; Arias M
Transplant Proc; 2008 Nov; 40(9):2903-5. PubMed ID: 19010142
[TBL] [Abstract][Full Text] [Related]
26. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft.
Slavcev A; Honsova E; Lodererova A; Pavlova Y; Sajdlova H; Vitko S; Skibova J; Striz I; Viklicky O
Transpl Immunol; 2007 Jul; 18(1):22-7. PubMed ID: 17584598
[TBL] [Abstract][Full Text] [Related]
27. Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study.
Delgado JC; Pavlov IY; Shihab FS
Transpl Immunol; 2009 Dec; 22(1-2):1-4. PubMed ID: 19772921
[TBL] [Abstract][Full Text] [Related]
28. Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft.
Pavlova Y; Viklicky O; Slatinska J; Bürgelova M; Süsal C; Skibova J; Honsová E; Striz I; Kolesar L; Slavcev A
Transpl Immunol; 2011 Jul; 25(1):72-6. PubMed ID: 21376809
[TBL] [Abstract][Full Text] [Related]
29. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
[TBL] [Abstract][Full Text] [Related]
30. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement.
Truong DQ; Darwish AA; Gras J; Wieërs G; Cornet A; Robert A; Mourad M; Malaise J; de Ville de Goyet J; Reding R; Latinne D
Transpl Immunol; 2007 Jun; 17(4):283-7. PubMed ID: 17493532
[TBL] [Abstract][Full Text] [Related]
31. Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome.
Ypsilantis E; Key T; Bradley JA; Morgan CH; Tsui S; Parameshwar J; Taylor CJ
J Heart Lung Transplant; 2009 Nov; 28(11):1206-10. PubMed ID: 19782609
[TBL] [Abstract][Full Text] [Related]
32. CD30, a marker to detect the high-risk kidney transplant recipients.
Spiridon C; Nikaein A; Lerman M; Hunt J; Dickerman R; Mack M
Clin Transplant; 2008; 22(6):765-9. PubMed ID: 19040559
[TBL] [Abstract][Full Text] [Related]
33. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation.
Heinemann FM; Rebmann V; Witzke O; Philipp T; Broelsch CE; Grosse-Wilde H
Transplantation; 2007 Mar; 83(6):706-11. PubMed ID: 17414702
[TBL] [Abstract][Full Text] [Related]
34. Soluble CD30 does not predict late acute rejection or safe tapering of immunosuppression in renal transplantation.
Valke LL; van Cranenbroek B; Hilbrands LB; Joosten I
Transpl Immunol; 2015 Jan; 32(1):18-22. PubMed ID: 25446808
[TBL] [Abstract][Full Text] [Related]
35. Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation.
Hamer R; Roche L; Smillie D; Harmer A; Mitchell D; Molostvov G; Lam FT; Kashi H; Tan LC; Imray C; Fletcher S; Briggs D; Lowe D; Zehnder D; Higgins R
Transpl Immunol; 2010 Aug; 23(4):161-5. PubMed ID: 20600903
[TBL] [Abstract][Full Text] [Related]
36. Assessment of different biomarkers provides valuable diagnostic standards in the evaluation of the risk of acute rejection.
Zheng J; Ding X; Tian X; Jin Z; Pan X; Yan H; Feng X; Hou J; Xiang H; Ren L; Tian P; Xue W
Acta Biochim Biophys Sin (Shanghai); 2012 Sep; 44(9):730-6. PubMed ID: 22759804
[TBL] [Abstract][Full Text] [Related]
37. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies.
Vaidya S; Partlow D; Barnes T; Thomas P; Gugliuzza K
Clin Transplant; 2006; 20(4):461-4. PubMed ID: 16842522
[TBL] [Abstract][Full Text] [Related]
38. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients.
Billing H; Sander A; Süsal C; Ovens J; Feneberg R; Höcker B; Vondrak K; Grenda R; Friman S; Milford DV; Lucan M; Opelz G; Tönshoff B
Transpl Int; 2013 Mar; 26(3):331-8. PubMed ID: 23279372
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of pre- and posttransplantation serum interferon-gamma and soluble CD30 for predicting liver allograft rejection.
Kim KH; Oh EJ; Jung ES; Park YJ; Choi JY; Kim DG; Lee KY; Kang CS
Transplant Proc; 2006 Jun; 38(5):1429-31. PubMed ID: 16797323
[TBL] [Abstract][Full Text] [Related]
40. Soluble CD30 for the prediction and detection of kidney transplant rejection.
Arjona A
Drug News Perspect; 2009 Sep; 22(7):409-13. PubMed ID: 19890498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
